All In Biotech

Drug Trial Radar · NCT03691623

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.

Last checked: Nov 19, 2026Latest source record: May 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Oct 15, 2018

Primary completion

Sep 30, 2019

Study completion Oct 18, 2019

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
hVIVO Services Limited
First posted
Oct 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.

Conditions

  • RSV Infection

Interventions

  • EDP-938 Dose 1Drug

    Oral suspension for 5 days

  • EDP-938 Dose 2Drug

    Oral suspension for 5 days

  • PlaceboDrug

    Oral suspension for 5 days

  • EDP-938 Dose 3Drug

    Oral suspension for 5 days

  • EDP-938 Dose 4Drug

    Oral suspension for 5 days

  • PlaceboDrug

    Oral suspension for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral LoadTime frame: Twice daily on Day 2 through Day 11 and once on Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • hVIVO Services Limited (hVIVO)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.